Melanoma MicroRNA signature predicts post-recurrence survival. - Wikidata - awgldk - TriplyDB

Melanoma MicroRNA signature predicts post-recurrence survival.

Melanoma MicroRNA signature predicts post-recurrence survival.

http://www.wikidata.org/entity/Q36327521

about

Clinical outcome prediction by microRNAs in human cancer: a systematic review Searching for the 'melano-miRs': miR-214 drives melanoma metastasis Expression and Function of miR-155 in Diseases of the Gastrointestinal Tract Classification of Indeterminate Melanocytic Lesions by MicroRNA Profiling.Regulation of cancer aggressive features in melanoma cells by microRNAs.Up-regulated Dicer expression in patients with cutaneous melanoma Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma MicroRNA signatures differentiate melanoma subtypes.A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells.Identifying microRNAs involved in aging of the lateral wall of the cochlear duct Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients.In-depth characterization of microRNA transcriptome in melanoma.microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C.Circulating microRNAs: potential biomarkers for cancer.Ensemble classifier based on context specific miRNA regulation modules: a new method for cancer outcome prediction.MicroRNAs as potential clinical biomarkers: emerging approaches for their detection.A microRNA signature associated with early recurrence in breast cancer.miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.miR-193b Regulates Mcl-1 in Melanoma.MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients Network-based survival-associated module biomarker and its crosstalk with cell death genes in ovarian cancer.Identification of metastasis-suppressive microRNAs in primary melanoma Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells--Evidence of unique microRNA cargos.E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry.A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.Revisiting determinants of prognosis in cutaneous melanoma.Serum microRNAs as biomarkers for recurrence in melanoma.Detection of Exosomal miRNAs in the Plasma of Melanoma Patients.miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value.Reduction of COX-2 through modulating miR-124/SPHK1 axis contributes to the antimetastatic effect of alpinumisoflavone in melanoma.Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma.Prognostic tissue markers in melanoma.The three M's: melanoma, microphthalmia-associated transcription factor and microRNA.Towards new therapeutic approaches for malignant melanoma.

P2860

Q24289183-55CEEDD4-03BE-4521-A0BB-2CAA1AC7295E Q24632823-ECF4147E-535E-46C8-91F6-9B5E5ACA59B3 Q26749058-8DC58344-5C6B-43A4-AC75-74105E04FDFF Q30276253-7B8FCAC4-699E-4773-B89A-DD1F25BB2E92 Q33889489-4228ACFE-7F69-47B9-8E22-A585906F6803 Q33940775-9B945883-B2AB-411F-8FC3-392978FBF2DB Q34031613-A01E295C-29EB-4DF8-A14D-A26FAD99B8F6 Q34182764-8A6D2D34-C9EE-47BE-B584-69DFF05F16FE Q34215802-51093371-B464-4912-9B7E-DA64EA8CFEB1 Q34304540-7D42AFAD-A498-4799-93A2-BA75E4674FE9 Q34535461-16460FCD-D397-487F-AD09-6B7000B3011C Q34713622-C3947FD2-CDB6-4CF7-ADBF-2889862F129A Q34735084-BBD12DBC-9CD8-4019-9E29-75C4A2705300 Q34984013-87EDF37C-C7D5-48DF-BC97-7325053E552B Q34993968-8CC4EC9B-4D7A-4475-AD04-9A220EACB879 Q35036105-163ED016-4E82-4A4E-85E4-C77C7C374437 Q35051536-024DA35D-BBF6-4C35-BB5E-A9DF91F2AC25 Q35053672-5F54AD75-22C8-4AC9-A46D-68515C01121A Q35121814-2D9FD060-FEA6-4688-BF05-88631A14320C Q35262736-706AA64E-944C-452D-8201-B55DBBD3F6AA Q35474400-AA5C82DB-DF3B-4A28-AA8C-DD022A9DDBFA Q35687295-24CEAD4F-2D99-48D6-9635-878195128957 Q35740150-3881D316-DD2C-4D05-9BBF-30EA32ECAC85 Q35769650-0D66042A-8267-4286-8311-2F35004CD226 Q36047432-0335391E-1D99-4531-A35A-8D7C880F4054 Q36191656-DF1B26CD-5451-4D6A-96CD-611F9528499C Q36235540-A699DEE1-1C5A-48B8-937C-686AB12E12FC Q36244744-F39A648A-8832-4A73-9EE6-1B3954610157 Q36286668-B6507746-593F-4E80-AE40-DC906393305A Q36338825-765DACB1-1311-4EC2-AC62-FFBEA4CAB63F Q36341127-9252CABD-C6B5-42A6-B646-04F063C2AC34 Q36409368-7D5AD316-90B9-404D-A74E-860717CFA5CB Q36926211-8961473F-32E8-43A2-A2A9-65C9117DA5CA Q37305975-1C896C5C-B7F8-4BC4-B9EB-6E98BC5827AE Q37328429-6949BB8A-7A1C-4AD5-B60B-29FDD6A42993 Q37732960-2AE3032E-9C8D-4075-B020-58EFB6CE8BDF Q37801939-5E589803-52BD-4CA7-BA1D-AA9BA588E8C1 Q37924320-9C13137A-2CDC-421D-9BDC-47825ED102A0 Q37946457-7B53158A-E980-445C-909B-A8380F3CBD71 Q37951743-8F4BBAB4-4072-4567-9154-7B499C866CDD

P2860

Melanoma MicroRNA signature predicts post-recurrence survival.

http://www.wikidata.org/entity/Q36327521

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Melanoma MicroRNA signature predicts post-recurrence survival.

@ast

Melanoma MicroRNA signature predicts post-recurrence survival.

@en

type

label

Melanoma MicroRNA signature predicts post-recurrence survival.

@ast

Melanoma MicroRNA signature predicts post-recurrence survival.

@en

prefLabel

Melanoma MicroRNA signature predicts post-recurrence survival.

@ast

Melanoma MicroRNA signature predicts post-recurrence survival.

@en

P1433

Q36327521-2B54A728-026B-4D20-AD67-D858BD28E23D

P1476

Q36327521-E4E1CCBF-BC2E-49A7-95DD-C5D1DB24A4CB

P2093

Q36327521-08C69252-48E4-40A8-B861-10CAEF8E60EE

Q36327521-0E7A56C3-AFA2-4F5B-A9A8-F4A3D92192CB

Q36327521-108F0CCF-D6A6-458F-BC99-E95B2325693B

Q36327521-2BFA11B0-6A8C-4457-A0D2-A55BCD4118AC

Q36327521-2FD77ED4-59CB-4569-B1B9-511C5DA59289

Q36327521-50D575E6-BE79-4CFB-8EFF-D6D2CF4D08C8

Q36327521-51A1A4C9-EB88-4071-97C4-BF2BA657E3FB

Q36327521-714AB193-AA5F-49A9-839A-06971BD0816C

Q36327521-82A41636-DD88-476F-AA01-4B9DEAA29B0F

Q36327521-AC4C65FF-D64E-4B97-A227-298A74381852

P2860

Q36327521-00FCD833-22BC-44CD-8ED1-7A815CAA4161

Q36327521-09E88608-3F2A-432E-8143-76B017965DAD

Q36327521-0FD28135-13C6-40C4-AD4B-66437C5CFB1A

Q36327521-1AD85B40-7A4F-42F8-9319-F29857DFAD2E

Q36327521-1DC57277-CD3A-4C2A-926D-01796901FAAA

Q36327521-237EF31A-5312-45A6-987D-5CCB9496BBFD

Q36327521-2C6749DF-43AB-4D37-BEEB-05F3F7A0EE63

Q36327521-313028C3-C66B-47B8-9C86-7239DCB56F6A

Q36327521-365AB4AF-ACD1-4A08-9872-F497CE6F7EF9

Q36327521-3FB134FC-C74C-417B-953D-30C2AD2EA333

P304

Q36327521-740A7708-3B13-438F-BCCC-EA4878314C6C

P31

Q36327521-3D658F2F-9F35-4310-9C47-E83A9CE22ACF

P356

Q36327521-40DADB2E-A888-4B4B-BE70-91F9C5272284

P407

Q36327521-FE8D83B7-F0BF-4D2D-8D2A-EBB6C27D8AC2

P433

Q36327521-20F5371A-1206-4CB6-B982-2FE4A44D3ECD

P478

Q36327521-73BB48C4-0A51-44D7-8B82-11B0066FF746

P577

Q36327521-EE26791C-7B7B-4027-BFA0-AC69F730DEC8

P5875

Q36327521-B9D7A899-EA63-4BBF-8476-C79FB4DD5284

P698

Q36327521-4B724CB9-B1E6-4FEE-BA1E-6128EDBFEFD5

P921

Q36327521-82362F9C-DE52-4E69-9409-F647ACC947B2

P932

Q36327521-6278E4F0-0291-49F9-9388-19EAC3185C5E

P356

1078-0432.CCR-09-2721

P1433

Clinical Cancer Research

P1476

Melanoma MicroRNA signature predicts post-recurrence survival.

@en

P2093

Amy E Rose

http://www.w3.org/2001/XMLSchema#string

Anna C Pavlick

http://www.w3.org/2001/XMLSchema#string

Avital Gaziel

http://www.w3.org/2001/XMLSchema#string

Douglas Hanniford

http://www.w3.org/2001/XMLSchema#string

Eva Hernando

http://www.w3.org/2001/XMLSchema#string

Farbod Darvishian

http://www.w3.org/2001/XMLSchema#string

Ilana Belitskaya-Lévy

http://www.w3.org/2001/XMLSchema#string

Iman Osman

http://www.w3.org/2001/XMLSchema#string

Jan Zakrzewski

http://www.w3.org/2001/XMLSchema#string

Miguel F Segura

http://www.w3.org/2001/XMLSchema#string

P2860

Bioconductor: open software development for computational biology and bioinformatics

Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing

microRNAs exhibit high frequency genomic alterations in human cancer

Accumulation of miR-155 and BIC RNA in human B cell lymphomas

Significance analysis of microarrays applied to the ionizing radiation response

p53 represses c-Myc through induction of the tumor suppressor miR-145

Inositol phosphatase SHIP1 is a primary target of miR-155

MicroRNA gene expression deregulation in human breast cancer

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

P304

1577-1586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-2721

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41548303

http://www.w3.org/2001/XMLSchema#string

P698

20179230

http://www.w3.org/2001/XMLSchema#string

P921

P932

4662869

http://www.w3.org/2001/XMLSchema#string